5-(4-(4-((dimethylamino)methyl)-3-fluoro-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-N,1-dimethyl-1H-indazole-3-carboxamide

ID: ALA4752008

Chembl Id: CHEMBL4752008

PubChem CID: 162653141

Max Phase: Preclinical

Molecular Formula: C20H22FN9O

Molecular Weight: 423.46

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CNC(=O)c1nn(C)c2ccc(Nc3nccc(-n4cc(CN(C)C)c(F)n4)n3)cc12

Standard InChI:  InChI=1S/C20H22FN9O/c1-22-19(31)17-14-9-13(5-6-15(14)29(4)26-17)24-20-23-8-7-16(25-20)30-11-12(10-28(2)3)18(21)27-30/h5-9,11H,10H2,1-4H3,(H,22,31)(H,23,24,25)

Standard InChI Key:  UXDHJZXXNJZCJZ-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4752008

    ---

Associated Targets(Human)

SYK Tclin Tyrosine-protein kinase SYK (7372 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SU-DHL-2 (105 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 423.46Molecular Weight (Monoisotopic): 423.1931AlogP: 1.85#Rotatable Bonds: 6
Polar Surface Area: 105.79Molecular Species: NEUTRALHBA: 9HBD: 2
#RO5 Violations: HBA (Lipinski): 10HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 12.69CX Basic pKa: 6.54CX LogP: 2.23CX LogD: 2.18
Aromatic Rings: 4Heavy Atoms: 31QED Weighted: 0.49Np Likeness Score: -1.94

References

1. Grimster NP,Gingipalli L,Barlaam B,Su Q,Zheng X,Watson D,Wang H,Simpson I,Pike A,Balazs A,Boiko S,Ikeda TP,Impastato AC,Jones NH,Kawatkar S,Kemmitt P,Lamont S,Patel J,Read J,Sarkar U,Sha L,Tomlinson RC,Wang H,Wilson DM,Zehnder TE,Wang L,Wang P,Goldberg FW,Shao W,Fawell S,Dry H,Dowling JE,Edmondson SD.  (2020)  Optimization of a series of potent, selective and orally bioavailable SYK inhibitors.,  30  (19): [PMID:32717371] [10.1016/j.bmcl.2020.127433]

Source